See more : Boston Scientific Corporation (BSX.F) Income Statement Analysis – Financial Results
Complete financial analysis of Diamond Biofund Inc. (6901.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Diamond Biofund Inc., a leading company in the Asset Management industry within the Financial Services sector.
- A & S Group (Holdings) Limited (1737.HK) Income Statement Analysis – Financial Results
- Sterling and Wilson Renewable Energy Limited (SWSOLAR.BO) Income Statement Analysis – Financial Results
- ICDS Limited (ICDSLTD.BO) Income Statement Analysis – Financial Results
- Lungteh Shipbuilding Co., Ltd. (6753.TW) Income Statement Analysis – Financial Results
- China Merchants Bank Co., Ltd. (CIHHF) Income Statement Analysis – Financial Results
Diamond Biofund Inc. (6901.TWO)
About Diamond Biofund Inc.
Diamond Biofund Inc. is a venture capital firm specializing in early to late stage investments. The firm typically invest in Greater China markets with focus in biotechnology, new drug development, innovative and high precision medical equipment, and medical services. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 137.59M | 102.43M | 404.44M | 64.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 137.59M | 102.43M | 404.44M | 64.46M |
| Other Expenses | 2.46M | -260.00K | -4.88M | -2.28M |
| Operating Expenses | 137.59M | 102.43M | 404.44M | 64.46M |
| Cost & Expenses | 137.59M | 102.43M | 404.44M | 64.46M |
| Interest Income | 861.00K | 120.00K | -663.00K | -694.00K |
| Interest Expense | 245.00K | 552.00K | 663.00K | 0.00 |
| Depreciation & Amortization | 11.47M | 11.86M | 12.02M | 10.56M |
| EBITDA | 892.83M | 2.97B | -392.42M | -53.90M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 881.37M | 2.96B | 6.10B | -367.78M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -245.00K | -552.00K | -5.54M | -2.98M |
| Income Before Tax | 881.12M | 2.96B | 6.09B | -370.76M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 83.34M | 108.98M | 1.84M | 110.00K |
| Net Income | 797.78M | 2.85B | 6.09B | -370.87M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 1.07 | 3.01 | 6.19 | -0.55 |
| EPS Diluted | 1.03 | 2.98 | 6.10 | -0.55 |
| Weighted Avg Shares Out | 749.30M | 948.72M | 983.23M | 674.37M |
| Weighted Avg Shares Out (Dil) | 773.21M | 954.86M | 998.50M | 674.37M |
Source: https://incomestatements.info
Category: Stock Reports